NasdaqCM - Delayed Quote USD

Celldex Therapeutics, Inc. (CLDX)

38.53 -1.10 (-2.78%)
At close: April 18 at 4:00 PM EDT
Advanced Chart
Loading Chart for CLDX
DELL
  • Previous Close 39.63
  • Open 39.41
  • Bid 38.48 x 100
  • Ask 38.55 x 100
  • Day's Range 38.31 - 39.80
  • 52 Week Range 22.11 - 53.18
  • Volume 536,448
  • Avg. Volume 944,091
  • Market Cap (intraday) 2.531B
  • Beta (5Y Monthly) 1.56
  • PE Ratio (TTM) --
  • EPS (TTM) -2.92
  • Earnings Date May 2, 2024 - May 6, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 70.71

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

www.celldex.com

160

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about Celldex Therapeutics, Inc.

Recent News: CLDX

View More
View More

Performance Overview: CLDX

Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CLDX
2.85%
S&P 500
5.06%

1-Year Return

CLDX
18.74%
S&P 500
20.71%

3-Year Return

CLDX
63.61%
S&P 500
19.73%

5-Year Return

CLDX
872.98%
S&P 500
72.77%

Compare To: CLDX

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

CLDX
Celldex Therapeutics, Inc.
38.53
-2.78%
Mkt Cap 2.531B
Industry Biotechnology
CGEM
Cullinan Therapeutics, Inc.
18.06
+1.01%
Mkt Cap 777.765M
Industry Biotechnology
EWTX
Edgewise Therapeutics, Inc.
15.45
-1.28%
Mkt Cap 1.439B
Industry Biotechnology
NUVL
Nuvalent, Inc.
63.06
-1.85%
Mkt Cap 4.04B
Industry Biotechnology
DNTH
Dianthus Therapeutics, Inc.
23.63
+1.24%
Mkt Cap 693.507M
Industry Biotechnology
JSPR
Jasper Therapeutics, Inc.
23.21
-2.56%
Mkt Cap 349.633M
Industry Biotechnology
ELVN
Enliven Therapeutics, Inc.
17.67
+2.14%
Mkt Cap 827.051M
Industry Biotechnology
MRUS
Merus N.V.
40.47
-1.41%
Mkt Cap 2.375B
Industry Biotechnology
BPMC
Blueprint Medicines Corporation
88.90
+0.59%
Mkt Cap 5.444B
Industry Biotechnology
ARVN
Arvinas, Inc.
34.29
+2.51%
Mkt Cap 2.342B
Industry Biotechnology
NGNE
Neurogene Inc.
31.58
-6.12%
Mkt Cap 405.898M
Industry Biotechnology

Statistics: CLDX

View More

Valuation Measures

As of 4/18/2024

  • Market Cap

    2.53B

  • Enterprise Value

    2.11B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    270.86

  • Price/Book (mrq)

    5.89

  • Enterprise Value/Revenue

    306.12

  • Enterprise Value/EBITDA

    -15.15

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -21.70%

  • Return on Equity (ttm)

    -37.45%

  • Revenue (ttm)

    6.88M

  • Net Income Avi to Common (ttm)

    -141.43M

  • Diluted EPS (ttm)

    -2.92

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    423.6M

  • Total Debt/Equity (mrq)

    0.59%

  • Levered Free Cash Flow (ttm)

    -46.7M

View More

Research Analysis: CLDX

View More

Analyst Price Targets

35.00
70.71 Average
38.53 Current
90.00 High
 

Fair Value

Overvalued
% Return
38.53 Current
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 
View More

People Also Watch

ACAD ACADIA Pharmaceuticals Inc.
17.07
-0.70%
 
FOLD Amicus Therapeutics, Inc.
10.33
-2.09%
 
HALO Halozyme Therapeutics, Inc.
37.81
-0.55%
 
EXEL Exelixis, Inc.
22.49
-1.66%
 
AGEN Agenus Inc.
4.9700
-7.96%
 
ALNY Alnylam Pharmaceuticals, Inc.
145.16
-0.11%
 
CYTK Cytokinetics, Incorporated
67.00
-1.37%
 
MACK Merrimack Pharmaceuticals, Inc.
14.68
0.00%
 
SRPT Sarepta Therapeutics, Inc.
116.55
-1.14%
 
AGIO Agios Pharmaceuticals, Inc.
29.43
+1.38%
 
PBYI Puma Biotechnology, Inc.
4.9900
-3.48%
 
DVAX Dynavax Technologies Corporation
11.34
-0.79%
 
PTCT PTC Therapeutics, Inc.
24.69
-1.87%
 
CRIS Curis, Inc.
15.22
-4.58%
 
SGMO Sangamo Therapeutics, Inc.
0.4851
-5.99%
 
BCRX BioCryst Pharmaceuticals, Inc.
4.5000
-1.75%